Methodological breakthroughs over the past four decades have repeatedly revolutionized
transcriptome profiling. Using RNA sequencing (RNA-seq), it has now become possible to …

Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer
and is a biomarker of cancer phenotype and disease progression. The ability of these …

Background Mantle-cell lymphoma is generally incurable. Despite high rates of complete
response after initial immunochemotherapy followed by autologous stem-cell …

Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains
incurable, and we are still unable to identify patients who will not benefit from the current …

Purpose Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose
considerable variability of individual outcome is associated with clinical characteristics …

Identifying new lead molecules to treat cancer requires more than a decade of dedicated
effort. Before selected drug candidates are used in the clinic, their anti-cancer activity is …

Mantle cell lymphoma (MCL) is an aggressive tumor, but a subset of patients may follow an
indolent clinical course. To understand the mechanisms underlying this biological …

Monoclonal antibodies are standard therapeutics for several cancers including the anti-
CD20 antibody rituximab for B cell non-Hodgkin lymphoma (NHL). Rituximab and other …

Under normal physiological conditions, cellular homeostasis is partly regulated by a balance
of pro-and anti-phagocytic signals. CD47, which prevents cancer cell phagocytosis by the …

In cancer cells, genetic alterations can activate proto-oncogenes, thereby contributing to
tumorigenesis. However, the protein products of oncogenes are sometimes overexpressed …